logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10226476 B1

PDFFull Text
Date of Patent:
Mar. 12, 2019

Filed:

Jul. 17, 2015

Method of attenuating reactions to skin irritants

Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

S. Brian Wilson, Lexington, MA (US);

Glenn Dranoff, Lexington, MA (US);

Silke Gillessen, St. Gallen, CH;

Assignee:

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorney:

Foley Hoag LLP

Primary Examiner:

Ernst V Arnold

Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/685 (2006.01); A61K 8/55 (2006.01); A61K 8/68 (2006.01); A61K 31/164 (2006.01); A61K 31/66 (2006.01); A61K 31/739 (2006.01); A61K 31/765 (2006.01); A61Q 7/00 (2006.01); A61Q 17/00 (2006.01); A61Q 19/00 (2006.01); A61K 31/133 (2006.01); A61K 31/661 (2006.01); A61K 31/7028 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 31/7032 (2006.01); A61K 47/60 (2017.01);
U.S. Cl.
CPC ...
A61K 31/685 (2013.01); A61K 8/553 (2013.01); A61K 8/68 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/00 (2013.01); A61K 31/133 (2013.01); A61K 31/164 (2013.01); A61K 31/66 (2013.01); A61K 31/661 (2013.01); A61K 31/7028 (2013.01); A61K 31/7032 (2013.01); A61K 31/739 (2013.01); A61K 31/765 (2013.01); A61K 47/60 (2017.08); A61Q 7/00 (2013.01); A61Q 17/00 (2013.01); A61Q 19/00 (2013.01); C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.

Find Patent Forward Citations

Loading…